Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 27, 2009

Anacor Partners with TB Alliance and Drugs for Neglected Diseases Initiative

  • Anacor Pharmaceuticals is reporting separate deals with the Global Alliance for TB Drug Development and Drugs for Neglected Diseases initiative (DNDi) that leverage its boron platform.

    Anacor is providing the TB Alliance with a nonexclusive, royalty-free worldwide license for TB. Both organizations will explore an antibacterial drug target with Anacor receiving support from the TB Alliance for its research efforts.

    The company also extended its license and drug development agreement with DNDi to develop therapeutics for African sleeping sickness, visceral leishmaniasis, and Chagas disease. Over the last 12 months, the partnership has moved from hit to lead series, according to Shing Chang, R&D director of DNDi. The terms of the arrangement give DNDi a nonexclusive, royalty-free license for any boron-based compound identified through the collaboration for neglected diseases for developing countries.

    Anacor’s other partners include GSK and Schering Plough. Its relationship with GSK involves development of systemic anti-infectives and is in the preclinical stage with four compounds.

    The drug partnered with Schering is also Anacor’s lead candidate. It is in Phase II studies as a treatment for onychomycosis. Other candidates being developed alone include a Phase II topical product for skin and nail infections, anti-inflammatories in Phase I and II development for psoriasis and atopic dermatitis, and compounds in early clinical studies for periodontal disease and acne.




    ♦♦♦
    Related News
    TB Alliance Scores $24M to Bolster Drug R&D (Mar. 24, 2009)
    TB Alliance and Sanofi-Aventis to Ally for R&D (Oct. 14, 2008)
    GSK and TB Alliance Extend Discovery Partnership by Three Years (Jan. 24, 2008)
    GSK Gains Access to Anacor’s Boron-Based Chemistry in Multibillion-Dollar Deal (Oct. 9, 2007)
    Anacor Could Make $625M in Deal with Schering-Plough (Feb. 2, 2007)



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »